JATT II Acquisition Corp.
JATT
NASDAQ Global Market11.00
USD
- -
- -
CIK
0002112446
ISIN
KYG507651092
CUSIP
G50765109
Return %
Stock
S&P500
1Y
4.76
18.21
3Y
4.76
64.38
5Y
4.76
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Someit Sidhu
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 153 Central Avenue, 56 Westfield NJ United States of America 07091
- IPO Date
- Apr 17, 2026
- CIK
- 0002112446
- Website
- jattacquisition.com
- Similar Companies
- Business
- JATT Acquisition Corp operates primarily as a special purpose acquisition company (SPAC) focusing on facilitating mergers, acquisitions, and business combinations primarily within the life sciences sector. The company's core activities involve investment income generation, advisory services, and management fees related to its acquisition and merger endeavors. JATT's revenue streams are diversified across investment income, advisory services, and management fees, with significant growth in investment income over recent years. In 2023, JATT Acquisition Corp completed a major business combination with Zura Bio Limited, a clinical-stage biotechnology company developing novel medicines for immune disorders, including treatments for Alopecia Areata and other inflammatory diseases. This strategic merger marked a significant expansion into biotechnology and life sciences. Following this, JATT announced plans to transfer its listing to NASDAQ to align with its evolved business direction. The company operates internationally, with key operations linked to the UK-based Zura Bio and related entities. Founded in 2021 and headquartered in Grand Cayman, Cayman Islands, JATT Acquisition Corp has demonstrated financial growth with increasing revenues supported by strategic acquisitions, market expansions, and partnerships with technology firms. As part of its growth strategy, JATT focuses on innovative product development in life sciences, leveraging collaborations and acquisitions to enhance its portfolio and market presence. The company's management team comprises experienced industry professionals with backgrounds in bioscience, immunology, and financial management, positioning JATT to capitalize on emerging opportunities in specialized healthcare and biotechnology markets. JATT's recent developments include the merger with Zura Bio, the Nasdaq transfer plan, and ongoing investments to expand its therapeutic portfolio, including advancing drug candidates like tibulizumab, ZB-168, and torudokimab. Overall, JATT Acquisition Corp functions as a vehicle for targeted acquisitions and development in life sciences, offering investment and advisory services while expanding its operational scope through recent strategic business combinations and market listing transitions. The company remains focused on growth through innovation, partnerships, and acquisitions in the biotechnology and healthcare sectors.
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
JATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)